Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

ABSTRACT:

Purpose

Tumor antigen-loaded dendritic cells (DC) are believed to activate antitumor immunity by stimulating T cells, and CTL-associated antigen 4 (CTLA4)-blocking antibodies should release a key negative regulatory pathway on T cells. The combination was tested in a phase I clinical trial in patients with advanced melanoma.

Experimental design

Autologous DC were pulsed with MART-1(26-35) peptide and administered with a dose escalation of the CTLA4-blocking antibody tremelimumab. Sixteen patients were accrued to five dose levels. Primary end points were safety and immune effects; clinical efficacy was a secondary end point.

Results

Dose-limiting toxicities of grade 3 diarrhea and grade 2 hypophysitis developed in two of three patients receiving tremelimumab at 10 mg/k

SUBMITTER: Ribas A 

PROVIDER: S-EPMC2765061 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature